FGFR2 and metabolic dysfunction-associated steatohepatitis: Thus, an ideal treatment selection criterion would comprise intrahepatic CCA subjects without NASH but attaining R0/R1 resection status with FGFR2 aberrations who are then recommended for futibatinib treatment.